Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Last Patient Last Visit Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Ocuphire initiates Global License Agreement for Nyxol eye drops across 3 indications

Nov 8, 2022

Ocuphire reaches license agreement for the development and commercialization of Nyxol

Nov 8, 2022

Ocuphire enters global license agreement with Famy for Nyxol development

Nov 8, 2022

Ocuphire Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops

Nov 7, 2022

Presbyopia: How are the Drops Performing?

Jul 10, 2022

Presbyopia-correcting drops broaden options for younger patients

Jul 1, 2022

So Many Options Coming! What Differences Do We See So Far?

Jun 1, 2022

Ocuphire Pharma's Mina Sooch

May 1, 2022

Ophthalmology Management eUpdate

Mar 9, 2022

Presbyopia Physician March 2022

Mar 1, 2022
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Next »
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use